Crystallization and Evaporation |
|||
| Session 557 - Polymorphism in Pharmaceutical Development | |||
| Presentations are solicited for polymorphism of substances related to the development of active pharmaceutical ingredients. This includes methods for discovering and producing the most stable form. The impact of form selection on a reproducible manufacturing process for a stable drug substance or formulated drug product is also of interest. Papers which examine strategies/methodologies for the control of polymorphism during crystallization, drying, storage and formulation are most welcomed. This may include but is not limited to the affect of solvent composition, particle size, shear environment, seeding and reactor configuration. The novel use of process analytical technologies for monitoring and control of crystallizations is also an important component to be covered in this session. | |||
| Chair: | Thomas LaPorte | ||
| CoChair: | Priscilla J. Hill | ||
| CoSponsor(s): | Pharmaceuticals |
||
| 557a | Concomitant Nucleation of Polymorphs Aniruddh Singh, In Sung Lee, Allan S. Myerson |
||
| 557b | Modeling and Prediction of the Crystal Structure of Pharmaceutical Co-Crystals Panagiotis G. Karamertzanis, Andrei V. Kazantsev, N. Issa, G. W. a. Welch, Claire S. Adjiman, Constantinos C. Pantelides, Sally L. Price |
||
| 557c | Crystallization and Polymorphism of Chiral Compounds Qi Gao, Alicia Ng |
||
| 557d | Pseudopolymorphic Transitions of Sodium Naproxen In Mixed-Solvent Systems Krystle J. Chavez, Ronald W. Rousseau |
||
| 557e | In-Situ Controlling and Monitoring of Polymorphic Crystallization and Transformation Xia Yang, Xiujuan Wang, Chi Bun Ching |
||
| 557f | Achieving Desired Polymorphs in API Process Development ChEnchi Wang, Qi Gao, Beth Sarsfiled, Yuping Qiu, Victor Rosso, Chiajen Lai, Daniel Hsieh, Shih-Ying Chang |
||
See more of Separations Division
See more of The 2008 Annual Meeting